Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous?

Updated Mar 7, 2025 | 01:00 AM IST

SummaryTwin-to-twin transfusion syndrome (TTTS) is a rare pregnancy complication in identical twins sharing a placenta, causing uneven blood flow, which can lead to severe health risks or fatal outcomes if untreated.
Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous

Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

  • 90% of the cases of untreated TTTS lead to loss of one or both twins.
  • Despite treatment, only a 70% survival rate for both twins is assured.
  • Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
  • Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

End of Article

ADHD: Your Pupils May Explain How The Brain Handles Attention, Says New Indian Study

Updated Sep 14, 2026 | 12:00 AM IST

SummaryA new study says that the pupils of children may hold certain attention-related physiological clues about ADHD that could shape future diagnostic tools.
Your Pupils May Explain How The Brain Handles Attention, Says New ADHD Study

Credit: AI

Your eyes may explain a lot about how your brain handles attention. A new Indian study suggests that tiny fluctuations in the pupils may provide a physiological clue to attention related differences in children with ADHD.

Researchers from the Indraprastha Institute of Information Technology Delhi analysed eye-tracking data from 50 children aged 10 to 12, including 28 children with combined-type ADHD and 22 without a neurodevelopmental diagnosis. These findings were published in Scientific Reports.

Instead of just looking at the size of the pupils, researchers examined how pupil responses shifted from one trial to another while children performed a working-memory task.

What ADHD-Related Clues Do Pupils Hold?

During the experiment, children watched dots appear on a grid and had to remember their positions while ignoring distractions. An eye tracker recorded their pupil diameter 1,000 times per second.

After accounting for age, IQ and memory-task difficulty, the researchers estimated that unmedicated children with ADHD had about 23% greater trial-to-trial variability in their pupil responses than children in the control group.

Among the unmedicated children with ADHD, greater pupil variability was also associated with poorer accuracy on the task.

The pattern was, however, more complicated. Within individual trials, pupil variability was actually lower in the ADHD group. This suggests that different measures of pupil dynamics may capture different aspects of attention and brain activity.

Also read: Increased Screen Timings Have Lead to ADHD: Key Symptoms

Effect Of ADHD Medication On The Pattern

The researchers also looked at 17 children with ADHD who completed the task both after taking their usual methylphenidate medication and after stopping it for 24 hours.

When the children were taking medication, their pupils showed a stronger response during the task and less variation between trials. Their overall pupil-response pattern also became more similar to that of the control group. But the researchers caution against interpreting this as proof that medication normalising attention span.

Methylphenidate can itself influence physiological systems that affect pupil size, meaning the study could not completely separate the drug's direct effects on the pupils from changes related to attention.

Also read: Using AI Apps To Manage ADHD? How They Can Help And Why Experts Urge Caution

Can A Pupil Test Diagnose ADHD?

There is no single biological test for ADHD currently. Diagnosis involves clinical assessment, developmental history and behavioural symptoms across different settings and circumstances.

The study itself has several limitations. For instance, it was based on a small sample, used existing eye-tracking data and involved a controlled laboratory task rather than everyday environments like classrooms.

Although the statistical model found greater trial-to-trial pupil variability, the direct participant-level difference between the ADHD and control groups did not remain statistically significant after correction for multiple comparisons.

The researchers therefore describe pupil dynamics as a useful source of additional physiological information, rather than a diagnostic test.

First author Saumya Yadav said, "It is still too early to consider pupil measurements as a clinical diagnostic tool.”

Larger studies will need to determine whether these pupil patterns can reliably distinguish ADHD from other conditions and whether they remain consistent outside laboratory settings.

End of Article

AI Analysed 400,000 Reddit Posts About Ozempic And Mounjaro And Found 2 Unusual Side-Effects Worth Noting

Updated Sep 13, 2026 | 10:00 PM IST

SummaryWith the help of artificial intelligence and real life experiences shared on Reddit, researchers were recently able to spot some of the uncommon side effects of GLP-1 drugs that did not show in clinical trials.
AI Analysed 400,000 Reddit Posts About Ozempic And Mounjaro: Here Are The Side Effects Worth Noting

Credit: AI

A recent AI analysis of more than 400,000 Reddit posts about popular GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound revealed several side effects that researchers may not have fully recorded in clinical trials.

The study, published in Nature Health, analysed 410,198 Reddit posts from May 2019 through June 2025. Researchers identified 67,008 people who self-reported using semaglutide or tirzepatide, with 43.5% reporting at least one side effect.

The findings do not prove that the drugs caused the symptoms. Instead, they did identify patterns in patients' own accounts that may need further investigation.

What Side Effects Did The AI Find?

As expected, the analysis found gastrointestinal symptoms in majority. Among GLP-1 users who reported side effects, the most common were:

  • Nausea: 36.9%
  • Fatigue: 16.7%
  • Vomiting: 16.3%
  • Constipation: 15.3%
  • Diarrhoea: 12.6%

Researchers also found abdominal pain, reduced appetite, acid reflux, bloating, headache and dizziness among commonly reported symptoms.

But two groups of symptoms stood out as they may be less represented in existing clinical-trial data and drug information. They are reproductive symptoms and complaints associated with temperature.

Nearly 4% of people who reported side effects described reproductive symptoms, including irregular menstrual cycles, bleeding between periods and heavy bleeding.

GLP-1 drug users also described chills, feeling unusually cold, hot flashes and fever-like sensations.

Also read: GLP-1 Drugs Mounjaro, Zepbound Show Promise For 1 Billion With Sleep Apnea

Effects Of Ozempic Or Mounjaro On Menstrual Cycles

The study was based on self-reported social-media posts, so researchers cannot establish whether semaglutide or tirzepatide directly caused menstrual changes, chills or hot flashes.

Other factors may also influence these symptoms. People taking GLP-1 drugs may experience substantial weight loss, changes in food intake, metabolic changes or other health changes that could effect these symptoms.

The researchers therefore describe these findings as safety signals, rather than confirmed adverse effects.

Also read: Are GLP-1 Drugs Actually Changing Asthma Biology, Or Are People Simply Having Fewer Attack Due To Weight Loss?

Reliability Of Reddit Analysis

Clinical trials help in determining whether a medication is effective. They also help in identifying its potential side-effects. But once millions of people begin using a drug, patients may describe symptoms in everyday settings that were uncommon or not specifically investigated during trials.

Reddit provides researchers with a huge data collection of real-world experiences. AI can quickly scan hundreds of thousands of posts for recurring symptom patterns that would be extremely difficult to identify manually.

However, Reddit users are not representative of all people taking GLP-1 drugs. The researchers noted that the population studied was younger, more likely to be male and disproportionately based in the US.

The study does not provide evidence that people should stop Ozempic, Mounjaro or other GLP-1 medications. Instead, it shows how AI-assisted analysis of patient experiences could help in addition to traditional drug-safety trials and monitoring.

Common symptoms of GLP-1 medications remain nausea, vomiting, diarrhoea and constipation as they are backed by extensive research and clinical trials.

The newly highlighted symptoms, particularly menstrual and temperature-related changes, need clinical research to determine whether they are genuinely caused by the drugs.

End of Article

Globally Popular Haircare Brand Sued Over Hair Relaxers & Cancer Risk: What Does The Science Say?

Updated Sep 13, 2026 | 06:30 PM IST

SummaryArizona Attorney General filed a lawsuit against L’Oréal USA, accusing the brand of selling chemical hair relaxers without disclosing cancer risks.
Globally Popular Beauty Brand Sued Over Hair Relaxers & Cancer Risk: What Does Science Say?

Credit: AI

Globally renowned beauty and haircare brand L’Oréal is in the midst of a new legal battle in the US over allegations that it did not warn consumers possible potential cancer risks linked with its chemical hair-relaxer products.

Arizona Attorney General Kris Mayes filed a consumer fraud lawsuit against L’Oréal USA, its parent company and SoftSheen, accusing the companies of selling chemical hair relaxers without disclosing alleged links to ovarian and uterine cancers. Arizona is the first US state to bring such a lawsuit against L’Oréal over the products.

The lawsuit alleges that the products were primarily marketed to African American women and, in some cases, children.

The state is seeking damages and penalties, including warnings if the brand wants to keep selling the products.

What Is The Concern With Hair Relaxers?

Chemical hair relaxers are highly alkaline products designed to permanently straighten textured hair. They work by breaking and reforming the disulfide bonds in keratin, which gives hair its natural shape.

According to the Arizona lawsuit, some chemical relaxer products contain substances including phthalates, parabens, and other chemicals classified as probable carcinogens.

The complaint states that repeated use can increase exposure as these products are applied directly onto the scalp.

However, the presence of a potentially hazardous chemical does not establish that using a particular product will cause cancer. Cancer risk depends on factors including the substance, dose, duration, and route of exposure.

Also read: Prostate Cancer: What's Fact, What's Fiction

Earlier Study Flags Same Concerns

The legal action follows years of scientific research that examined links between chemical hair relaxers and cancers related to hormones.

A 2022 study from the US National Institutes of Health found that women who reported frequent use of chemical hair-straightening products had more than twice the risk of developing uterine cancer compared with women who did not use them frequently.

The researchers, however, found an association, not proof that hair relaxers directly caused these cancers.

Other research has also investigated possible links with ovarian and breast cancers, adding to concerns about repeated exposure to chemicals may cause serious health conditions.

Also read: Beyond Vaccines And Nutrition: Why Childhood Cancer Needs A Wider Conversation

What Does L’Oréal Say?

According to Reuters, L’Oréal has rejected the allegations. A spokesperson for L’Oréal USA said that the company is confident in the safety of its products and considers that the claims lack legal and scientific merit.

The company said, “L’Oréal’s highest priority is the health and well-being of all our consumers. Our products are subject to a rigorous scientific evaluation of their safety by experts who also ensure that we strictly follow all regulations in every market in which we operate. We are confident in the safety of SoftSheen-Carson’s products and believe the allegations made in this lawsuit have neither legal nor scientific merit.”

L’Oréal also disputes the research underlying the litigation, saying the study cited by plaintiffs did not establish a causal connection between hair-relaxer use and the alleged health conditions and called for further research.

The Arizona lawsuit comes amid more than 12,000 similar lawsuits consolidated in a federal multidistrict litigation in Chicago involving L’Oréal, Revlon and other manufacturers. Trials in that litigation may start in 2027.

The current evidence does not mean that everyone who has used a chemical hair relaxer will develop cancer.

But repeated use is an area of ongoing scientific investigation. People who use these products can reduce unnecessary exposure by following product instructions carefully, avoiding application to irritated or damaged skin, and considering less frequent use or non-chemical alternatives.

End of Article